Table II.
A comparison of baseline characteristics among NYHA class III patients in 4 primary prevention ICD randomized controlled trials
| DEFINITE (N = 96) | MADIT I (N = 33) | MADIT II (N = 271) | SCD-HeFT (N = 496) | P value* | |
|---|---|---|---|---|---|
| ICD treatment | 47 (49.0) | 15 (45.5) | 171 (63.1) | 251 (50.6) | .004 |
| Age (y), mean (SD) | 57.83 (14.1) | 63.58 (8.6) | 64.42 (10.7) | 59.84 (11.9) | .787 |
| Male sex | 65 (67.7) | 31 (93.9) | 225 (83.0) | 356 (71.8) | <.001 |
| Race | <.001 | ||||
| Black | 25 (26.0) | 3 (9.1) | 24 (8.9) | 100 (20.2) | |
| White | 66 (68.9) | 29 (87.9) | 237 (87.5) | 362 (73.0) | |
| Other | 5 (5.2) | 1 (3.0) | 10 (3.70) | 34 (6.9) | |
| Ischemic cardiomyopathy | 0 (0) | 33 (100) | 271 (100) | 277 (55.9) | <.001 |
| Hypertension | 0 (NA) | 16 (48.5) | 151 (55.9) | 300 (60.5) | .234 |
| Diabetes | 28 (29.2) | 3 (9.1) | 100 (36.9) | 186 (37.5) | .005 |
| Hyperlipidemia | 0 (NA) | 9 (37.5) | 0 (NA) | 0 (NA) | NA |
| LVEF, mean (SD) | 20.02 (6.4) | 22.45 (6.7) | 21.40 (5.8) | 23.15 (7.1) | <.001 |
| Prior CABG | 0 (NA) | 19 (57.6) | 162 (59.8) | 140 (28.2) | <.001 |
| Prior MI | 0 (0) | 33 (100) | 271 (100) | 237 (47.8) | <.001 |
| Prior PCI | 0 (NA) | 7 (21.2) | 113 (42.0) | 122 (24.6) | <.001 |
| LBBB | 0 (NA) | 4 (12.9) | 54 (21.7) | 110 (22.2) | .477 |
| QRS duration (ms), mean (SD) | 116.7 (30.5) | 125.9 (31.7) | 126.6 (33.8) | 121.5 (30.4) | .612 |
| Antiarrhythmic drug | 8 (8.3) | 9 (27.3) | 11 (4.1) | 0 (0) | <.001 |
| β-Blocker | 73 (76.0) | 3 (9.1) | 166 (61.3) | 301 (60.7) | <.001 |
| ACE inhibitor | 82 (85.4) | 20 (60.6) | 214 (79.0) | 470 (94.8) | <.001 |
| GFR* (mL/min/1.73 m2) | .013 | ||||
| ≥60 | 0 (NA) | 11 (35.5) | 137 (50.7) | 278 (56.4) | |
| <60 to ≥30 | 0 (NA) | 19 (61.3) | 109 (40.4) | 193 (39.2) | |
| <30 | 0 (NA) | 1 (3.2) | 24 (8.9) | 22 (4.5) | |
| AF | 31 (32.3) | 0 (NA) | 0 (NA) | 46 (9.3) | <.001 |
| Peripheral vascular disease | 1 (1.04) | 6 (18.2) | 0 (NA) | 0 (NA) | .900 |
| Pulmonary disease | 16 (16.7) | 0 (NA) | 0 (NA) | 132 (26.6) | .053 |
| Smoking | 98 (96.9) | 22 (73.3) | 214 (79.0) | 370 (74.6) | <.001 |
NA, not available.
*
Comparison limited to trials with available data. NA denotes that the indicated trial was not included in the comparison because the relevant data were not collected at baseline.